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Introduction: We investigated the association between glucose tolerance status and trajectories of change in
blood glucose, and cognitive function in adults aged 25 to 85.
Methods: The sample (n = 4547) was drawn from a national, population-based cohort study in Australia (AusDiab).
Fasting plasma glucose (FPG), glycated haemoglobin (HbA1c) and general health were assessed at 0, 5 and 12 years.
Covariates included age, education, body mass index, blood pressure and physical activity. At 12 years, participants
completed assessments of memory, processing speed and verbal ability.
Results: Known diabetes at baseline was associated with slower processing speed at 12 years in both younger
(25–59 years) and older (>60 years) age-groups. After 12 years of follow-up, adults aged < 60 with diabetes at
baseline had a mean speed score of 49.17 (SE = 1.09) compared with 52.39 (SE = 0.20) in normals. Among younger males
without diagnosed diabetes, reduced memory at 12 years was associated with higher HbA1c at 5 years (β = −0.91,
SE = 0.26, p < 0.001). No effects were apparent for females or older males. Adjusting for insulin sensitivity (HOMA-%S)
and hs-C reactive protein attenuated these associations, but depression and CVD risk did not. Latent class analysis was
used to analyse the associations between trajectories of HbA1C and glucose over 12 years, and cognition. Identified
classes were described as 1) normal and stable blood glucose over time (reference), 2) high intercept but stable blood
glucose over time, and 3) increasing blood glucose over time. In both young males and females, high stable glucose
measures were associated with poorer cognitive function after 12 years.
Conclusion: Those with type 2 diabetes, younger males with high non-diabetic HbA1c, and adults with high stable
blood glucose are at increased risk of poorer cognition. The findings reinforce the need for management of diabetes
risk factors in midlife.Introduction
Recent research on both middle-aged adults [1] and
older adults [2] has shown that type 2 diabetes increases
the risk of late-life cognitive decline, Alzheimer’s disease
(AD) and all-cause dementia [3–5]. Some authors have
argued that the critical period for the effect of type 2
diabetes on cognition is in late life [6], rather than middle
age. Recent data, however, show associations between type
2 diabetes and mild cognitive impairment (MCI) in middle
age (50–65 years old) [7], and between type 2 diabetes and
cognitive decline in mid-life [8]. There is also growing* Correspondence: kaarin.anstey@anu.edu.au
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cognitive decline. Studies report a direct association be-
tween glycaemia and risk of dementia in older adults with
and without diabetes [3], as well as associations between
poor glucose metabolism and reduced executive function
in mid-life [9], between insulin resistance and brain atro-
phy in middle age [10], and between high fasting blood
glucose and lower memory scores, hippocampal atrophy
and reduced hippocampal microstructure in older adults
(≥60 years old) without diabetes [11, 12].
Current understanding of the role of glycaemic control
and ageing in the transition to cognitive impairment is
limited by a lack of longitudinal data on the relation-
ship between blood glucose and cognition. One recent
study found that longitudinal trajectories of glycatedrticle distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
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(N = 835) predict cognitive performance, specifically ex-
ecutive function [13]. The only study to our knowledge
that has examined longitudinal change in HbA1c and cog-
nition in those with normal glucose tolerance (NGT) [14]
did so in a sample of older adults (≥75 years old, N = 101)
and found a decrease of 1.37 Mini-Mental State Examin-
ation (MMSE) points per 1 % increase in HbA1c. Analysis
of the Whitehall II mid-life cohort found that cognitive
change in prediabetes and new diabetes was not different
from that in NGT [15].
Data on the relationship between glucose tolerance
and cognition in mid-life, particularly in prediabetic stages,
are sparse [5]. We therefore evaluated how glucose toler-
ance status, fasting plasma glucose (FPG) and HbA1c over
12 years were associated with cognitive abilities including
processing speed, memory and verbal ability in adults aged
25–59 and 60–85. We hypothesised that type 2 diabetes
and glycaemia would be associated with poorer cognition
in both younger and older age groups and with increased
risk of cognitive impairment in the older group. Our
cohort was assessed at 0, 5 and 12 years on measures of
glycaemia and diabetes status, and cognition was assessed
at 12 years.
Methods
Study population
The Australian Diabetes, Obesity and Lifestyle Study
(AusDiab) is a national population-based survey under-
taken to determine the prevalence and incidence of dia-
betes, obesity and other cardiovascular disease risk factors
in Australian adults. The baseline study was conducted in
1999–2000 and involved 11,247 adults aged 25 years and
above, from across Australia. Sample selection involved
drawing a stratified cluster sample from 42 randomly se-
lected census collector districts across Australia. Details of
the sampling process have been described elsewhere [16].
Information was collected using a brief household inter-
view, followed by a biomedical examination. Among those
who completed the household interview, the response
rate for the baseline biomedical examination was 55 %
(n = 11,247). The first follow-up (n = 6537) was con-
ducted in 2004–2005 (i.e., 5-year follow-up), where all
living eligible participants were invited to attend the
follow-up. Participants from the baseline survey were
classed as ineligible for follow-up if they refused contact,
were deceased, had moved overseas, were in high-level
nursing care or reported a terminal illness. The second
follow-up was conducted in 2011–2012. Of the 4614 par-
ticipants who attended the interview, cognitive assessment
was conducted on 4562 adults. At each follow-up, in-
formation was collected on demographics, medical and
family history, lifestyle risks including level of physical
activity, diet, alcohol and tobacco consumption, physicalmeasurements, and blood and urine measurements. Cog-
nitive assessment was conducted at the second follow-up
only (i.e., 12-year follow-up).
Standard protocol approvals and participant consent
Written informed consent for research was obtained from
all participants in the study, and the research protocol was
approved by the human research ethics review boards of
the International Diabetes Institute, Monash University
and the Alfred Hospital, Melbourne.
Diabetes status and blood glucose measures
All participants except for those currently receiving treat-
ment for diabetes and those who were pregnant under-
went a standard 75 g oral glucose tolerance test (OGTT)
[17]. At baseline, the FPG and 2-hour plasma glucose
(PG) levels were determined by a glucose oxidase method
using an Olympus AU600 automated analyser (Olympus
Optical, Tokyo, Japan). At Wave 2, a spectrophotometric
hexokinase method using a Roche Modular (Roche
Diagnostics, Indianapolis, IN, USA) was used. At Wave 3, a
hexokinase method using a Siemens Advia 2400 (Siemens
AG, Munich, Germany) was used. Procedures for com-
paring results from the different assays are described else-
where [18]. Total HbA1c analysis used high-performance
liquid chromatography (Bio-Rad Variant Hemoglobin
Testing System; Bio-Rad, Hercules, CA, USA) with stan-
dardised conversion to A1c values. High-sensitivity
C-reactive protein (hs-CRP) was measured in stored sam-
ples (−80 °C) via a two-site chemiluminescent immuno-
assay (BioMediq IMMULITE 2000; CA, USA).
Glucose tolerance status was classified according to the
1999 World Health Organization criteria [17]. Briefly,
participants were classified as having ‘known diabetes’
(KDM) if they reported having doctor-diagnosed diabetes
and were either taking hypoglycaemic medication or had
FPG ≥7 mmol/l or 2-hour PG ≥11.1 mmol/l. Participants
not reporting diabetes but with FPG ≥7 mmol/l or 2-hour
PG ≥11.1 mmol/l were classified as having ‘newly diag-
nosed diabetes’ (NDM). For participants not reporting dia-
betes, impaired glucose tolerance (IGT) was classified
with FPG <126 mg/dl and 2-hour PG between 140 and
199 mg/dl. Impaired fasting glucose (IFG) was classi-
fied if FPG was between 110 and 125 mg/dl and 2-hour
PG <140 mg/dl. NGT was indicated by both FPG <110
mg/dl and 2-hour PG <140 mg/dl. Insulin sensitivity was
estimated from FPG and fasting insulin concentrations
using Homeostatic model assessment (HOMA-2), which
was calculated with the HOMA-2 program [19].
Anthropometry and blood pressure
Height and weight measures were taken at each wave,
from which the body mass index (BMI) was calculated.
Blood pressure measurements at Waves 2 and 3 were
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automated monitor (Dinamap Pro-Series Monitor Model
DP 101-NIBP, pulse and recorder; GE Medical Systems,
Freiburg, Germany). The mean of the first two measure-
ments were taken. At baseline, blood pressure was mea-
sured in the same manner for all states except Victoria,
where a manual sphygmamometer was used. These
measures were then adjusted to be comparable with auto-
mated methods. Mean arterial blood pressure (MAP) was
calculated as [20]:
MAP ¼ diastolic þ 1=3  systolic – diastolicð Þð Þ
Physical activity
The level of physical activity was determined using ques-
tions relating to time (in minutes) spent walking and
time spent doing vigorous and moderate physical activity
in the previous week [21].
Cognitive measures
Memory was assessed with the California Verbal Learning
Test (CVLT) [22]. In this test, participants listened to a list
of 16 common shopping list items read by the interviewer,
and subsequently repeated as many of these items as pos-
sible (immediate recall). Repeat learning trials were not
administered. After a delay of 20 minutes filled with other
non-verbal survey items, the participant was asked to re-
call the list a second time (delayed recall). Scores range
from 0 to 16. Vocabulary and verbal knowledge were
assessed using a lexical decision task, the Spot-the-Word
(STW) test [23]. In this test, participants were presented
with 60 pairs of words. One was a real word and one a
non-word, and the participant was required to identify the
real word. Scores range from 0 to 60. Performance on this
task correlates with verbal knowledge and is relatively
resistant to age-related decline. Processing speed was
assessed with the Symbol–Digit Modalities test (SDMT)
(oral version) [24]. Participants used a reference key to find
and report the numbers corresponding to a series of geo-
metric figures as quickly as possible. The score ranged from
0 to 60 and represents the number of correct responses
given within a 90-second period. A global screening test for
cognitive impairment, the MMSE [25], was also included
and administered to individuals aged above 40 years, with
scores below 24/30 indicating cognitive impairment.
Statistical analyses
Comparisons between those lost to follow-up or who
did not complete the cognitive tests and those included
in the study were conducted using t tests and chi-square
tests. Individuals reporting type 1 diabetes were excluded
from analyses leading to a final sample of 4547, all with
a follow-up time of 12 years. Generalised linear models
(GLM) were used to estimate the associations ofdiabetes status at baseline and 5 years, with cognitive
function at 12 years, using case-wise exclusion for miss-
ing data. In the second set of analyses, participants with
KDM at any wave or NDM at the 12-year follow-up were
excluded, leaving a sample of 3515 participants. GLM
were used to estimate the association of glucose and
HbA1c at baseline, 5 years and 12 years with cognitive
function at 12 years, with case-wise exclusion for miss-
ing data. Covariates included age, education, BMI, smok-
ing, MAP and exercise. Analyses were stratified by sex
and age group (25–59 years, 60+ years). A significance
level of p <0.01 was used for interpretation of results.
In the final set of analyses, latent class analysis was
used to identify patterns of change in FBG and HbA1c
over 12 years. Classes of change (stable normal, stable
high normal, increasing) were then examined in rela-
tion to cognitive outcomes at 12 years using GLM.
Results
The analytic sample comprised 4547 participants (2032
men) with cognitive data at the third wave of follow-up.
Compared with the AusDiab sample at recruitment (N =
11,247), the study sample did not differ in gender dis-
tribution but was younger (mean 48.9 vs. 53.3 years,
p <0.001), had lower BMI (26.6 vs. 27.3, p <0.001), spent
more time exercising (285 vs. 266 minutes, p <0.01), was
less likely to smoke (p <0.01) had higher levels of educa-
tion (p <0.001) and had lower FPG (5.5 vs. 5.7, p <0.001)
and HbA1c (5.2 vs. 5.3, p <0.001). However, loss to follow-
up and attrition due to death meant that the analytic
sample was healthier than the baseline sample. Sample
attrition was 37 % at 5 years and 35 % at 12 years. At-
trition due to death was 9.5 % and 15 % at each follow-
up respectively. Analysis of glucose tolerance status as
a function of death status at 12 years (see Additional
file 1) indicated that those who had died prior to the
third wave of data collection were more likely to be classi-
fied as KDM and IGT, and less likely to be classified as
NGT at baseline (χ2 (4) = 510.94, p <0.001) and at 5 years
(χ2 (4) = 97.35, p <0.001). They also had higher mean
HbA1c at baseline (F(1, 11143) = 330.71, p <0.001) and at
5 years (F(1, 6438) = 60.80, p <0.001), and higher mean
FBG at baseline F(1, 11209) = 295.66, p <0.001) and at 5
years (F(1, 11209) = 295.66, p <0.001). Of the sample used
in this study, 95 participants had KDM at baseline, 169 at
the 5-year follow-up and 310 at the 12 year follow-up.
There were 77 cases of incident diabetes at the 5-year
follow-up (one KDM case reverted to IGT) and 111 inci-
dent cases at the 12-year follow-up (nine cases reverting
to IGT, IFG, new diabetes or NGT).
Participant characteristics
The participant characteristics are shown in Table 1 by
glucose tolerance status at baseline. The NGT group was
Table 1 Baseline characteristics and cognition at 12 years according to glucose tolerance status at baseline
NGT IFG IGT NDM KDM
(N = 3606) (N = 254) (N = 428) (N = 119) (N = 94)
Age range 25–83 25–83 25–85 25–79 36–75
Age, mean (SD) 47.71 (11.04) 51.31 (10.6)* 53.99 (11.1)* 56.6 (10.5)* 56.4 (9.4)*
Female (%) 2060 (57.1) 65 (25.6)* 249 (58.2) 56 (47.1) 48 (44.0)
BMI, mean (SD) (kg/m2) 25.9 (4.3) 28.5 (4.1)* 28.9 (5.3)* 30.1 (5.5)* 30.6 (6.0)*
Waist circumference, mean (SD) (cm)
Female 81.8 (11.6) 91.7 (12.4)* 91.0 (13.6)* 96.05 (14.2)* 98.7 (14.0)*
Male 95.1 (10.2) 100.8 (10.4)* 100.2 (10.8)* 103.7 (11.7)* 104.7 (14.2)*
Highest level of education (%)
Secondary school 1138 (31.7) 86 (34.3) 174 (40.7)* 48 (41.0) 39 (36.0)
Trade certificate 1055 (29.4) 91 (36.3) 115 (26.9) 38 (32.5) 37 (34.3)
Tertiary 1397 (38.9) 74 (29.5)* 138 (32.3) 31 (26.5) 32 (29.6)
Current smoker (%) 390 (11.0) 38 (15.1) 33 (7.8) 7 (6.0) 11 (10.1)
Ex-smoker (%) 960 (27.0) 92 (36.7)* 149 (35.1)* 39 (33.3) 42 (38.5)
Blood pressure, mean (SD) (mmHg)
Systolic 124.42 (15.7) 130.97 (16.3* 134.06 (17.2)* 143.19 (19.7)* 141.58 (19.9)*
Diastolic 69.10 (11.1) 73.80 (11.2)* 72.31 (11.7)* 77.40 (11.7)* 74.80 (11.1)*
Fasting blood glucose, mean (SD) (mg/dl) 94.41 (7.0) 113.69 (3.6) 100.54 (10.1)* 131.17 (31.2)* 171.71 (66.7)*
HbA1c, mean (SD) (%) 5.04 (0.2) 5.29 (0.26)* 5.27 (0.3)* 5.90 (1.0)* 7.30 (1.6)*
Exercise mean (SD) (minutes/week) 295.0 (338.9) 275.5 (335.4) 216.02 (260.7)* 236.14 (290.0)* 301.9 (357.6)
Cognition at 12 years, mean (SD)
MMSE score 28.14 (1.94) 27.6 (2.19)* 27.6 (2.4)* 26.9 (3.5)* 27.3 (2.8)*
CVLT score 6.64 (2.4) 6.10 (2.4)* 5.87 (2.4)* 5.59 (2.3)* 5.32 (2.4)*
STW score 49.94 (5.7) 49.29 (7.1) 50.1 (5.5) 49.54 (8.1) 48.98 (7.6)
SDMT score 50.9 (11.2) 47.30 (11.27)* 46.9 (12.6)* 42.34 (12.57)* 41.44 (12.57)*
SI conversion factors: HbA1c to mmol/mol, multiply values by 0.01; fasting blood glucose to mmol/l, multiply by 0.055
BMI body mass index, CVLT California Verbal Learning Test, HbA1c glycated haemoglobin, IFG impaired fasting glucose, IGT impaired glucose tolerance,
KDM known diabetes mellitus, MMSE Mini-Mental Status Examination, NDM new diabetes mellitus, NGT normal glucose tolerance, SD standard deviation,
SDMT Symbol–Digit Modalities test, STW Spot the Word
*Significantly different from NGT at p <0.05 (with Bonferroni correction)
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cept STW. NDM differed from the other diabetes status
groups with regard to exercise. Participant characteris-
tics also differed between the sexes (Additional file 1).
Within the NGT group, males (relative to females) had
higher systolic blood pressure, higher diastolic blood pres-
sure, higher BMI, higher FPG, higher HbA1c and were
more likely to have smoked, but did more exercise. There
were no sex differences in terms of age, verbal ability or
education.
Glucose tolerance status as a predictor of cognitive
function 7 and 12 years later
Table 2 presents the means of 12-year cognitive tests
according to glucose tolerance status at baseline and 5
years. KDM at baseline and at 5-year follow-up was a
predictor of slower processing speed at 12 years offollow-up for both age groups. Sex by glucose tolerance
status interactions were non-significant for memory and
processing speed (data not shown).
HbA1c and blood glucose as predictors of cognitive
function
Models estimating the associations of HbA1c and FPG
(measured at baseline, 5 years and 12 years) with cogni-
tive performance at 12 years for participants without
diabetes showed significant sex by HbA1c interactions
(β = −2.57, standard error (SE) = 1.3, p <0.05) and sex
by FPG interactions (β = −2.12, SE = 0.73, p <0.01), and
therefore models were stratified by gender (see Table 3).
For males in the younger age group, higher HbA1c at 5
years (β = −0.91, SE = 0.26, p <0.01) predicted poorer
memory performance. In this group, there were also trends
suggesting poorer memory, verbal ability and processing
Table 2 Marginal means for cognitive scores at 12 years of follow-up stratified by age group and diabetes status as baseline and 5-year and 12-year follow-up
Speed Memory Verbal
Baseline 5 years 12 years Baseline 5 years 12 years Baseline 5 years 12 years
Glucose tolerance
status
Mean (SE) N Mean (SE) N Mean (SE) N Mean (SE) N Mean (SE) N Mean (SE) N Mean (SE) N Mean (SE) N Mean (SE) N
25–59 years
NGT 52.39 (0.20) 2982 52.09 (0.23) 2506 51.99 (0.25) 2699 6.75 (0.05) 2962 5.23 (0.17) 2492 6.73 (0.61) 2686 50.06 (0.12) 2943 50.09 (0.14) 2480 50.09 (0.15) 2675
IFG 51.71 (0.64) 192 51.86 (0.81) 121 52.06 (0.67) 184 6.84 (0.16) 194 5.50 (0.36) 121 7.04 (0.17) 182 49.57 (0.39) 189 49.67 (0.50) 120 50.0 (0.41) 179
IGT 53.29 (0.54) 287 52.19 (0.68) 177 52.64 (0.53) 309 6.52 (0.13) 287 4.78 (0.27) 178 6.76 (0.13) 307 50.12 (0.33) 283 50.44 (0.42) 174 49.89 (0.33) 300
New diabetes
mellitus
50.51 (1.04) 73 51.52 (1.12) 61 51.62 (0.70) 173 6.56 (0.26) 71 5.00 (0.43)* 61 6.34 (0.17) 171 50.44 (0.65) 68 50.64 (0.70) 58 49.59 (0.43) 171
Known diabetes
mellitus
49.17 (1.09) 66 36.82 (0.92) 95 49.49 (0.88) 105 6.29 (0.28) 65 4.97 (0.33) 95 6.38 (0.22) 104 49.40 (0.67) 64 48.81 (0.57) 92 49.55 (0.55) 99
60–85 years
NGT 38.81 (0.67) 584 37.24 (0.78) 458 39.36 (0.85) 433 5.27 (0.14) 512 6.78 (0.06) 467 5.06 (0.18) 441 50.09 (0.14) 491 51.22 (0.57) 447 51.78 (0.64) 416
IFG 38.60 (1.47) 52 38.98 (1.64) 45 36.44 (1.90) 37 5.40 (0.31) 54 6.80 (0.20) 45 4.46 (0.37) 40 49.07 (0.50) 46 49.12 (1.23) 42 48.92 (1.31) 39
IGT 37.26 (1.03) 127 37.24 (1.22) 97 36.36 (1.18) 111 4.95 (0.22) 127 6.47 (0.17) 48 4.97 (0.25) 113 50.44 (0.42) 120 51.35 (0.92) 85 51.23 (0.90) 107
New diabetes
mellitus
35.15 (1.63) 42 38.98 (2.01) 27 37.18 (1.38) 71 5.09 (0.35) 43 6.20 (0.28) 27 5.12 (0.30) 70 50.64 (0.70) 40 52.09 (1.45) 27 51.67 (1.06) 66
Known diabetes
mellitus
35.10 (1.61) 41 36.82 (1.51) 27 34.76 (1.44) 63 4.56 (0.36) 39 6.33 (0.23) 51 4.51 (0.31) 63 49.59 (0.57) 40 48.59 (1.11) 52 49.70 (1.09) 61
Models adjusted for age, sex, education, BMI, smoking, exercise time and mean arterial blood pressure. Scores for speed range from 0 to 60; scores for memory range from 0 to 16; and verbal ability ranges from 0 to 60
BMI body mass index, NGT normal glucose tolerance, IFG impaired fasting glucose, IGT impaired glucose tolerance, SE standard error
**p <0.001, *p <0.05 relative to NGT
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Table 3 Associations of baseline and 5-year FPG and HbA1c with 12-year cognitive function in non-diabetic participants stratified by sex
Speed Memory Verbal
Males Females Males Females Males Females
β (SE) n β (SE) n β (SE) n β (SE) n β (SE) n β (SE) n
HbA1c, 25–59 years
Baseline –1.52 (1.06) 1192 0.63 (0.95) 1541 –0.56* (0.26) 1188 –0.20 (0.25) 1534 –1.60* (0.67) 1196 –0.93 (0.55) 1544
5 years –1.55 (1.07) 1165 1.30 (0.92) 1501 –0.91** (0.26) 1161 –0.13 (0.24) 1493 –1.58* (0.66) 1169 –0.50 (0.53) 1504
12 years –1.61* (0.68) 1181 0.19 (0.71) 1526 –0.24 (0.17) 1177 0.35 (0.19) 1518 –0.83 (0.43) 1185 –0.01 (0.41) 1529
HbA1c, 60–85 years
Baseline –0.05 (2.11) 260 –4.82 (2.47) 301 –0.29 (0.49) 262 –0.36 (0.54) 299 0.00 (1.64) 265 –3.32 (1.91) 304
5 years 2.15 (2.10) 251 –1.85 (2.53) 292 0.19 (0.49) 253 –0.42 (0.55) 290 1.17 (1.64) 256 –0.63 (1.88) 295
12 years 0.59 (1.62) 259 –1.62 (1.83) 291 0.24 (0.37) 260 –0.48 (0.41) 291 –0.19 (1.25) 263 –0.31 (1.42) 294
FPG, 25–59 years
Baseline –1.23* (0.54) 1202 0.97 (0.54) 1556 –0.08 (0.13) 1198 0.02 (0.14) 1549 –0.43 (0.35) 1206 0.35 (0.32) 1559
5 years –1.33* (0.53) 1165 0.59 (0.47) 1501 0.02 (0.13) 1161 –0.09 (0.13) 1493 –0.18 (0.33) 1169 0.10 (0.27) 1504
12 years –0.73 (0.38) 1182 0.27 (0.36) 1528 0.07 (0.09) 1178 0.10 (0.10) 1520 –0.14 (0.24) 1186 0.09 (0.21) 1531
FPG, 60–85 years
Baseline 1.40 (1.12) 262 –1.75 (1.27) 301 0.23 (0.26) 264 –0.30 (0.27) 299 –0.58 (0.87) 267 0.14 (0.98) 304
5 years 0.13 (0.89) 251 –0.89 (1.16) 292 –0.15 (0.20) 253 –0.31 (0.25) 290 0.31 (0.69) 256 –0.31 (0.86) 256
12 years 1.28 (0.89) 259 –1.62 (0.87) 291 0.24 (0.20) 260 –0.08 (0.19) 291 –0.19 (0.69) 263 –0.53 (0.68) 294
Models adjusted for age, education, BMI, smoking, exercise time and mean arterial blood pressure
BMI body mass index, FPG fasting plasma glucose, HbA1c glycated haemoglobin, SE standard error
*p <0.05; **p <0.01
Anstey et al. Alzheimer's Research & Therapy  (2015) 7:48 Page 6 of 11speed in young males with high blood glucose levels
(p <0.05). Specifically, these were poor memory and
verbal ability in those with high baseline HbA1c (mem-
ory: β = −0.56, SE = 0.26, p <0.05; verbal: β = −1.60,
SE = 0.67, p <0.05), and high HbA1c at 5 years (verbal:
β = −1.58, SE = 0.66, p <0.05), reduced processing speed
in those with high 12-year HbA1c (β = −1.61, SE = 0.68,
p <0.05), and high FPG at baseline (β = −1.23, SE = 0.54,
p <0.05) and 5 years (β = −1.33, SE = 0.53, p <0.05); how-
ever, these did not reach the conservative criterion for sig-
nificance (p <0.01). There were no associations between
HbA1c or FPG and cognition in females or in older males.Fig. 1 a) Latent class analysis identified three main patterns of change in F
decline in verbal skills relative to participants with low stable HbA1c. c) Hig
years. CVLT California Verbal Learning Test, FPG Fasting Plasma Glucose, HbAAll models were adjusted for age, education, BMI, smok-
ing, MAP and exercise.
Patterns of change in blood glucose over 12 years, and
cognitive outcomes
For individuals without type 2 diabetes, latent class ana-
lysis was conducted to identify categories of change in the
HbA1c and FBG measures over time. For both age groups,
and both blood glucose measures, a three-class outcome
fit the data best. Identified classes were described as: (1)
normal and stable blood glucose over time (reference); (2)
high intercept but stable blood glucose over time; and (3)BG and HbA1c over time. b) High-stable HbA1c was associated with
h stable FBG was associated with reduced memory performance at 12
1c glycated haemoglobin, STW Spot the Word
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‘high stable’ and ‘increasing’ classes were small relative to
the reference group. The three-class outcome for HbA1c
for the younger age group is shown in Fig. 1a. For males
aged <60 years, models estimating the association between
class of HbA1c change and cognition at 12 years revealed
that a high, stable pattern of HbA1c levels (N = 24) pre-
dicted lower verbal ability (β = −2.94, p = 0.008) relative
to individuals with normal and stable HbA1c levels (N =
1448) (Fig. 1b). This association remained after adjusting
for baseline age, education, smoking, BMI, exercise and
MAP (β = −3.00, p = 0.006). The pattern of change in
HbA1c over time did not predict speed of processing or
episodic memory at 12 years for young males, and no
associations were found for FPG change and cognition
(Fig. 1c). For females aged <60 years, high stable FPG
(N = 27) predicted lower episodic memory at 12 years
(β = −1.25, p <0.001) relative to the reference group (N =
1495) (Fig. 1c), and this remained after adjustment for
covariates (β = −0.885, p = 0.010). No other associations
occurred between pattern of blood glucose over time and
cognition. There were no associations between cognitive
outcomes and pattern of HbA1c or FPG levels for older
males or older females.
Glucose tolerance status, HbA1c and blood glucose as
predictors of global cognitive impairment
The MMSE was administered to individuals aged 60
years and older as a measure of global cognition. In models
adjusting for demographics, new diabetes and IFG at base-
line were associated with increased risk of global cognitive
impairment after 12 years of follow-up. However, these ef-
fects become non-significant after adjusting for BMI, level
of physical activity and MAP (Additional file 1). HbA1c
and FPG were not associated with cognitive impairment
(results not shown).
Models examining the association between latent class
of HbA1c change and MMSE at 12 years showed a signifi-
cant relationship between increasing HbA1c levels (N =
19) and lower MMSE scores (β = −1.44, p <0.01) relative
to normal, stable HbA1c levels (N = 1543). There was no
association between class of FPG change over time and
MMSE scores. Models were adjusted for baseline age,
education, smoking, BMI, exercise and MAP.
Sensitivity analyses
Results possibly occurred due to reverse causation, whereby
individuals with lower cognitive function are predisposed to
develop diabetes. To further evaluate this issue we re-
estimated the effect of diabetes status on processing speed,
adjusting for 12-year verbal ability since verbal ability
changes little over time: baseline (β = −2.635, SE = 1.06,
p <0.001) and 5 years (β = −1.810, SE = 0.90, p = 0.044).
KDM remained a risk factor for slower processing speed inthe 25–59 year group but the effect in the older group
became non-significant. For individuals without diabetes at
12 years, HbA1c at 5 years remained a significant predictor
of memory at 12 years for young males (p <0.01), and
remained non-significant for females and older males. Re-
moval of participants with MMSE <24 did not alter results.
Adjustment for cardiovascular risk, depression, insulin
sensitivity and C-reactive protein
Significant relationships in the above analyses were fur-
ther examined by separately adjusting for Framingham
cardiovascular disease 10-year percentage risk, depressive
symptoms (Center for Epidemiologic Studies Depression
Scale- Revised, CESD-R), HOMA-2 insulin sensitivity and
hs-CRP (see Additional file 2). All observed associations
for young males remained after adjusting for depression
and cardiovascular risk. The association between baseline
FPG and processing speed in young males was non-
significant after adjusting for insulin sensitivity (β = −1.01,
SE = 0.59, p >0.05). Figure 2a shows this relationship in
the HOMA-2 adjusted model for young females and
males. Insulin sensitivity was also significantly lower in
young males (mean (SE) = 58.9 (0.95)) than females (mean
(SE) = 63.4 (0.83), p <0.01) (Additional file 2). Figure 2b
shows that although there was a trend for lower process-
ing speed with lower insulin sensitivity, predicted SDMT
scores were lower across all quintiles of insulin sensitivity
in males relative to females. After adjusting for hs-CRP,
FPG at 5 years no longer predicted processing speed at 12
years in young males (β = −1.23, SE = 0.67, p >0.05). The
cross-sectional relationship between HbA1c at 12 years
and processing speed was also non-significant in young
males (β = −0.74, SE = 0.83, p >0.05). Figure 2c shows that
adjusting for hs-CRP diminished the relationship most for
males with very high HbA1c levels (new diabetes group).
Mean CRP levels were significantly higher among young
females (mean (SE) = 4.18 (7.85) mg/l) than males (mean
(SE) = 3.22 (6.61) mg/l, p <0.01). Figure 2d shows that
there is nevertheless a trend for reduced processing speed
with higher CRP in both males and females. Although ele-
vated CRP was associated with higher blood glucose (new
diabetes) in the 25–59 year age group, this was not the
case in the older group (data not shown).
Discussion
This large population-based study examined how change
in HbA1C is associated with future cognitive performance,
and is one of the few studies to examine the relationship
between type 2 diabetes, glycaemia and cognition in both
younger and older adults. We found that type 2 diabetes
was associated with slower processing speed, after 7 and
12 years of follow-up. This was observed after adjusting
for verbal ability, education and other potential con-
founders and for adults aged younger than 60 years as
Fig. 2 Adjustment for insulin sensitivity and inflammation in models of glycaemia and processing speed (SDMT) at 12 years for participants
aged 25–59 years with no known diabetes. a Association after adjustment for insulin sensitivity (HOMA-%S) for males and females (25–59 years).
b Model-predicted SDMT as a function of sex and quintiles of insulin sensitivity (low sensitivity indicates greater insulin resistance). c Association after
adjustment for hs-CRP (inflammatory marker) as a function of diabetic status. d Model-predicted SDMT as a function of sex and quintiles of hs-CRP
(higher values indicate greater inflammation). Error bars represent ±1 standard error of the mean. HbA1c glycated haemoglobin, HOMA-2 Homeostatic
Model Assessment, hs-CRP high-sensitivity C-reactive protein, IFG impaired fasting glucose, IGT impaired glucose tolerance, New Diab new diabetes
SDMT Symbol–Digit Modalities Test
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out type 2 diabetes followed for 7 years, we found that
higher HbA1C was associated with poorer memory. Trends
in the data also suggested that baseline HbA1c and baseline
and 5-year FPG were associated with slower processing
speed in younger males. Insulin sensitivity and the in-
flammatory marker hs-CRP contributed to this associ-
ation in younger males, whereas cardiovascular risk and
depressive symptoms did not. No effect of glycaemia on
cognition was found for younger females or for older
males and females. Young males with persistently highlevels of HbA1c over the 12-year study period had lower
verbal ability than those with lower, stable HbA1c levels.
Young females with persistently high levels of HbA1c
had poorer memory at 12 years. Thus, our data suggest
that persistently high levels of blood glucose over time
in younger adults (<60 years) without type 2 diabetes
are associated with lower cognitive performance.
Our findings are consistent with recent results for non-
demented older adults showing that diabetes is related to
slowed speed of processing [26]. Our data are unable to
shed light on causal associations. Possible explanations of
Anstey et al. Alzheimer's Research & Therapy  (2015) 7:48 Page 9 of 11our findings include that reduced cognition may impact
on self-management of diabetes risk and, by this means,
increase the incidence of diabetes. Alternatively, diabetes
may lead to structural brain changes which result in
cognitive changes [26]. Recent neuroimaging research
supports the view that high glucose levels in people
without diabetes affects multiple brain sub-regions, in-
cluding lower grey/white matter regional volumes in the
frontal cortices [27]. Our findings are also consistent with
findings in older adults linking high non-diabetic blood
glucose levels with poor performance in verbal memory
and learning [12, 28], reduced hippocampal volume [11, 28]
and hippocampal microstructure [12].
Recent randomised controlled trials, however, indicate
that strict glycaemic control does not slow the rate of
cognitive decline in type 2 diabetes patients when com-
pared with standard diabetes management [29], although
brain volume loss was reduced in those undergoing in-
tensive glycaemic control. Management of other factors
such as vascular risk factors in target at-risk groups has
been proposed as a better approach to preventing cogni-
tive impairment and decline [5].
Sex differences in the association between glycaemia and
cognitive function have rarely been investigated [9, 27].
Our finding of more cardiovascular risk factors, higher
blood glucose and reduced memory in young, non-diabetic
males (see Additional file 1) is consistent with some re-
ports [27] and with broader findings that, in mid-life, males
have an elevated risk of vascular disease [30], more cere-
bral white matter lesions [31], greater insulin resistance
and glycaemia [32], and are diagnosed with type 2 diabetes
at lower BMI than females [33]. A recent report showed
that the medial temporal lobe is particularly sensitive to
vascular risk factors in older men compared with women
[34]. Although adjustment for cardiovascular risk did
not alter the findings, insulin sensitivity—which was also
reduced in men relative to women—did influence the link
between glycaemia and cognition.
Although only a small number of individuals showed a
consistent pattern of change in blood glucose in our sam-
ple (i.e., high stable, or increasing), our findings represent
the only data to our knowledge on the association between
cognition and the pattern of change in blood glucose over
time in adults without type 2 diabetes. We found that per-
sistently high levels of FPG and HbA1c over time are a
marker of poorer episodic memory in females (decrease of
0.89 words recalled) and poorer verbal ability (decrease of
3.0 words) in males aged <60 years. In contrast to previous
work on older adults showing correlated change in MMSE
scores with HbA1c levels over time [13], we found no asso-
ciation between the pattern of HbA1c change and cogni-
tive outcome at 12 years in our sample of older adults. The
lack of findings for older adults in our study should be
interpreted with caution because it may reflect the greaterimpact of attrition due to death in those with high HbA1c
and FBG levels, and greater effect of this biased attrition
in the older group than the younger group (see Additional
file 3).
In our study, cardiovascular risk did not attenuate the
observed link between glycaemia and cognition in men
aged younger than 60 (see Additional file 4). Our models
also included other vascular risk factors including hyper-
tension (MAP), smoking and BMI—which have been con-
sistently associated with cognitive decrements in the
general population and in those in prediabetic stages [5].
In our study, after adjustment for vascular risk factors,
only insulin sensitivity and CRP contributed to the ob-
served relationship. There is a growing understanding that
insulin resistance may mediate the relationship between
chronic high-fat diets and reduced cognition, both in rat
models and in humans with type 2 diabetes, while at the
same time contributing to cardiovascular disease, depres-
sion and hypertension [35]. Recent models of cognitive
impairment in type 2 diabetes and prediabetes propose
insulin resistance as part of a mechanism leading to
microvascular and neuronal metabolic insults within the
brain [5, 36]. Apparent from Fig. 2b, however, is that, even
among those with high insulin sensitivity, males had
slower processing speed than females, suggesting there are
other factors contributing to the observed sex difference.
Although adjustment for insulin sensitivity ameliorated
the association of HbA1c to processing speed, the rela-
tionship between HbA1c and memory remained significant
after adjusting for insulin sensitivity. This contrasts with a
recent report that insulin resistance predicts temporal
lobe atrophy as well as memory performance (Rey's
Auditory Verbal Learning Test) in a largely normogly-
caemic middle-aged cohort (57.66 ± 6.48 years) [10].
Levels of the inflammatory marker hs-CRP influenced the
association between Wave 3 HbA1c and processing speed.
Notably, this adjustment appeared to have the greatest ef-
fect for men with very high HbA1c (in the new diabetes
group), who also had higher hs-CRP levels.
Our study was limited by the lack of longitudinal cog-
nitive data and a measure of executive function. The sample
was biased towards healthy and more educated participants,
and attrition due to mortality was correlated with elevated
glycaemia and diabetes status. Study strengths include the
large sample size, inclusion of younger adults and measure-
ment of memory and processing speed, longitudinal data on
glucose tolerance status and glucose levels, and relevant
covariates.
Conclusions
Both type 2 diabetes and higher levels of HbA1C among
men without diabetes may increase the risk of poor cog-
nitive function and potentially increase the risk of cogni-
tive impairment. Adults with persistently high HbA1C
Anstey et al. Alzheimer's Research & Therapy  (2015) 7:48 Page 10 of 11within the normal range are at risk of poorer cognitive
function and may be a new target for intervention for
prevention of future cognitive decline. Longitudinal re-
search is urgently needed to examine how varying levels
and trajectories of HbA1C influence cognitive decline in
adulthood so that clinical advice can be developed for
optimal cognitive health in ageing.
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